Page 3 - Nasdaq Fdmt News Today

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,220,000 shares, a drop of 18.1% from the December 15th total of 3,930,000 shares. Based on an average daily volume of 366,600 […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Disc Medicine (NASDAQ:IRON – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Volatility and Risk 4D Molecular Therapeutics […]

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month […]

Royal Bank of Canada initiated coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report published on Thursday, Briefing.com reports. The brokerage issued an outperform rating and a $25.00 target price on the stock. Several other equities analysts have also commented on FDMT. HC Wainwright restated a buy rating and set […]

SVB Leerink upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) from a market perform rating to an outperform rating in a report published on Wednesday, Briefing.com reports. The brokerage currently has $24.00 price objective on the stock. Several other research firms also recently weighed in on FDMT. HC Wainwright restated a buy rating […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) was upgraded by equities researchers at SVB Leerink from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, Briefing.com reports. The brokerage presently has a $24.00 price objective on the stock. SVB Leerink’s price target would suggest a potential upside […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Equities researchers at HC Wainwright raised their Q3 2023 earnings per share estimates for 4D Molecular Therapeutics in a research note issued on Thursday, August 10th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.78) for the quarter, […]

Chardan Capital restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report released on Friday morning, Benzinga reports. The firm currently has a $31.00 target price on the stock. A number of other equities research analysts have also issued reports on FDMT. HC Wainwright reiterated a buy […]

HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock. Other research analysts also recently issued reports about the company. Chardan Capital boosted their price objective on […]